As Biotechnology companies, Adaptimmune Therapeutics plc (NASDAQ:ADAP) and OPKO Health Inc. (NASDAQ:OPK) are our subject to contrast. And more specifically their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

In table 1 we can see Adaptimmune Therapeutics plc and OPKO Health Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of Adaptimmune Therapeutics plc and OPKO Health Inc.

Risk and Volatility

Adaptimmune Therapeutics plc has a beta of 1.55 and its 55.00% more volatile than S&P 500. OPKO Health Inc.’s 113.00% more volatile than S&P 500 volatility due to the stock’s 2.13 beta.

Liquidity

Adaptimmune Therapeutics plc has a Current Ratio of 8.5 and a Quick Ratio of 8.5. Competitively, OPKO Health Inc.’s Current Ratio is 1.1 and has 1 Quick Ratio. Adaptimmune Therapeutics plc’s better ability to pay short and long-term obligations than OPKO Health Inc.

Analyst Recommendations

The Ratings and Recommendations for Adaptimmune Therapeutics plc and OPKO Health Inc. are featured in the next table.

Adaptimmune Therapeutics plc’s consensus target price is $7.5, while its potential upside is 365.84%.

Institutional and Insider Ownership

The shares of both Adaptimmune Therapeutics plc and OPKO Health Inc. are owned by institutional investors at 73.4% and 26.4% respectively. Insiders held 0.22% of Adaptimmune Therapeutics plc shares. On the other hand, insiders held about 5.5% of OPKO Health Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Adaptimmune Therapeutics plc’s stock price has bigger decline than OPKO Health Inc.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma. It is also developing MAGE A-10 peptide that is in Phase I/II clinical trials to treat urothelial (bladder), melanoma, and head and neck cancers, as well as NSCLC; AFP SPEAR T-cell therapeutic candidate that has completed preclinical testing for targeting a peptide associated with hepatocellular carcinoma; and MAGE-A4 to treat urothelial (bladder), melanoma, head and neck, esophageal and gastric, and ovarian cancer, as well as NSCLC. It has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a collaboration agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companyÂ’s Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companyÂ’s pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.